Meabco A/S expands combination
trials with more existing anti-cancer drugs
The European
Patent Office (EPO) informs that it has decided to grant a European
Patent (Anti-Cancer) for the BP-C1 drug.
MEABCO’S BP-Cx-1 widens the number of first line cytostatic agents
Continuation into phase IIB trials.